Table 1.
Clinical characteristics of patient.
| Variables |
Patients (n = 44) |
Responders (n = 20) |
Non-responders (n = 24) |
|---|---|---|---|
| Age | |||
| Median | 59 | 60 | 57.5 |
| Range | 29–76 | 29–74 | 30–76 |
| Gender | |||
| Male | 31 (70.45%) | 16 (80.00%) | 15 (62.50%) |
| Female | 13 (29.55%) | 4 (20.00%) | 9 (37.50%) |
| Number of previous treatment lines | |||
| 0–1 | 36 (81.82%) | 16 (80.00%) | 20 (83.33%) |
| ≥2 | 8 (18.18%) | 4 (20.00%) | 4 (16.67%) |
| Response of previous treatment lines | |||
| Response | 10 (22.73%) | 3 (15.00%) | 7 (29.17%) |
| Non-response | 25 (56.82%) | 8 (40.00%) | 17 (70.83%) |
| NA or NR | 9 (20.45%) | 9 (45.00%) | 0 |
| Type of metastatic sites | |||
| Lymph nodes | 29 (65.91%) | 15 (75.00%) | 14 (58.33%) |
| Bone | 11 (25.00%) | 4 (20.00%) | 7 (29.17%) |
| Liver | 8 (18.18%) | 4 (20.00%) | 4 (16.67%) |
| Lung | 6 (13.64%) | 3 (15.00%) | 3 (12.50%) |
| Pleura | 6 (13.64%) | 2 (10.00%) | 4 (16.67%) |
| Others | 12 (27.27%) | 6 (30.00%) | 6 (25.00%) |
| Number of metastatic lesions | |||
| 1 | 18 (40.91%) | 7 (35.00%) | 11 (45.83%) |
| ≥2 | 26 (59.09%) | 13 (65.00%) | 13 (54.17%) |
| Cancer type | |||
| Lung adenocarcinoma | 14 (31.82%) | 3 (15.00%) | 11 (45.83%) |
| Lung squamous cell carcinoma | 10 (22.73%) | 6 (30.00%) | 4 (16.67%) |
| Esophageal carcinoma | 5 (11.36%) | 2 (10.00%) | 3 (12.50%) |
| Colorectal carcinoma | 2 (4.55%) | 1 (5.00%) | 1 (4.17%) |
| Cholangiocarcinoma | 2 (4.55%) | 1 (5.00%) | 1 (4.17%) |
| Nasopharyngeal carcinoma | 2 (4.55%) | 1 (5.00%) | 1 (4.17%) |
| Lung small cell carcinoma | 2 (4.55%) | 0 | 2 (8.33%) |
| Lung large cell carcinoma | 1 (2.27%) | 1 (5.00%) | 0 |
| Gastric adenocarcinoma | 1 (2.27%) | 1 (5.00%) | 0 |
| Tongue squamous cell carcinoma | 1 (2.27%) | 1 (5.00%) | 0 |
| Duodenal adenocarcinoma | 1 (2.27%) | 0 | 1 (4.17%) |
| Renal cell carcinoma | 1 (2.27%) | 1 (5.00%) | 0 |
| Hepatocellular carcinoma | 1 (2.27%) | 1 (5.00%) | 0 |
| Malignant melanoma | 1 (2.27%) | 1 (5.00%) | 0 |